Research Paper Volume 8, Issue 12 pp 3520—3534
Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer
Figure 6C. Apoptosis measurements in HepG2 p53_/_ cells or huh cells after treatment with 0.02μM doxorubicin plus sFlt1 (concentrated conditioned medium) for 24h and for 48h. HepG2 p53-/-cells and huh7 cells exhibited increased apoptosis in response to combination treatment *p < 0.05, vs sFlt1 plus low-dose doxorubicin group.